Brain Imaging Changes Following Proton Therapy for Pediatric Primary Central Nervous System and Base of Skull Tumors
Assessment of Predicted LET and Dosimetry in Relation to White Matter Changes in Pediatric Patients Following Proton Therapy for Primary Central Nervous System and Base of Skull Malignancies: A Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To establish linear energy transfer (LET)-based models as early predictors for white matter changes on magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) sequences in pediatric patients following proton beam therapy for primary central nervous system (CNS) and base of skull tumors.
OUTLINE:
Patients' medical charts are reviewed.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic in Arizona
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients must have histologically confirmed central nervous system of skull base tumors
- Patient is going to undergo central nervous system (CNS) or base of skull proton beam therapy
Exclusion Criteria:
- Patients who have received prior therapeutic radiotherapy to the primary brain tumor site
- Patients who are unable to maintain follow-up through the Phoenix Children's Hospital and Mayo Clinic Arizona
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Observational (medical chart review)
Patients' medical charts are reviewed.
|
Review of medical chart
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
White matter changes within the central nervous system (CNS) following proton beam therapy using magnetic resonance imaging (MRI) sequences
Time Frame: At 18 months
|
The concordance of predicted linear energy transfer linear (LET) values with radiographic white matter changes will be analyzed utilizing a one sample t-test.
Will the compare concordance over time to evaluate if there is an increase, utilizing repeated measures mixtures models.
|
At 18 months
|
|
White matter changes within the CNS following proton beam therapy using diffusion tensor imaging (DTI) sequences
Time Frame: At 18 months
|
The concordance of predicted LET values with radiographic white matter changes will be analyzed utilizing a one sample t-test.
We will the compare concordance over time to evaluate if there is an increase, utilizing repeated measures mixtures models.
|
At 18 months
|
|
Relative biological effectiveness (RBE) predictions
Time Frame: Up to 18 months
|
Will compare concordance over time to evaluate if there is an increase, utilizing repeated measures mixtures models.
|
Up to 18 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
White matter changes within the CNS following proton beam therapy using DTI and MRI
Time Frame: Up to 18 months
|
Will assess the white matter changes within the CNS following proton beam therapy using DTI and MRI and determine concordance with predicted RBE values and biological dose.
|
Up to 18 months
|
|
Dose-volume effect and predicted LET distribution
Time Frame: Up to 18 months
|
Will be correlated.
Will evaluate the percent of concordance of isodose volumes with white matter changes utilizing pairwise t-tests and repeated measures mixed models.
|
Up to 18 months
|
|
White matter changes identified on imaging, and predict concordance
Time Frame: Up to 18 months
|
Will be described with both clinical acute and late toxicities following proton beam therapy.
Exploratory analyses utilizing tests for association and appropriate regression techniques will be conducted to determine the association of dose volume histogram, LET, RBE, and clinical factors on acute and late toxicities caused by white matter changes.
|
Up to 18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Tamara Z. Vern-Gross, D.O., Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MC1777 (Mayo Clinic in Arizona)
- NCI-2020-01197 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 18-002279 (Other Identifier: Mayo Clinic Institutional Review Board)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.